Investigational drug for returning myeloma after transplant
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug for people whose multiple myeloma has returned after a stem cell transplant. The goal is to see if it can control the cancer, and you must be healthy enough to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your multiple myeloma has come back after a stem cell transplant.
- You have had at least 2 prior treatments for your myeloma (before or after the transplant).
- You have not taken immunosuppressant drugs for at least 1 month and have no active graft-versus-host disease.
- You are physically active (can do light work; ECOG score 0-1).
- You have not received a prior CAR-T therapy that targets BCMA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This study tests a new type of cell therapy, called CAR-T, for people newly diagnosed with myeloma who can't have a stem cell transplant. The therapy uses your own immune cells, changed in a lab to better fight the myeloma cells.
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.